United States flu vaccine market is expected to reach nearly US$ 3 Billion by 2024. Growth in US flu vaccine market can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against flu vaccine and introduction of quadrivalent flu vaccine.
Flu Vaccine Market Research Report 2017 to 2024 presents an in-depth assessment of the Flu Vaccine including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Flu Vaccine investments from 2017 till 2024.
The research study focuses on Flu Vaccine major leading industry players with information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. In this report, the Flu Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2024, growing at a CAGR of XX% between 2016 and 2024.
Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024 provides a deep and thorough evaluation of the United States flu vaccine market. The report provides an in-depth analysis of the flu vaccination pattern in both Children and Adults in the United States. It also provides essential insights into flu vaccine production, price, consumption, supply, distribution, demand and specification. It also covers reimbursement pattern and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials and promising flu vaccines in the clinical development. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the US flu vaccine market such as Sanofi Pasteur, GSK and Seqirus. The major market players are evaluated on various parameters such as company overview, product outlook, latest development & trends and sales analysis of flu vaccine market from 2011 to 2022. The report also entails major drivers and inhibitors in the US flu vaccine market.
Avail Complete research data at: https://www.marketinsightsreports.com/report/purchase/08213068?mode=su
The report provides a basic overview of the Flu Vaccine industry including definitions, classifications, applications and industry chain structure. And development policies and plans are discussed as well as manufacturing processes and cost structures.
Long–term Growth Projection and Development:
- Sanofi to Acquire Protein Sciences Corporation
- It is likely that more than 185 Million persons being vaccinated with flu vaccines in 2024.
- Nearly 160 Million doses of flu vaccines have shipped to US for the 2017-2018 flu season
- It is projected that GSK flu vaccine sales value will reach around US$ 1.5 Billion by 2024
- BiondVax reports positive phase 2b clinical trial results for its universal flu vaccine
Key Companies Covered in This Report:
- Sanofi Pasteur
Major Flu Vaccines Covered Under This Report Are:
- Fluzone High Dose
- Fluzone Quadrivalent
- Intradermal (ID) Trivalent
- Fluarix Quadrivalent
- Flulaval Quadrivalent
- Flucelvax Quadrivalent
- Afluria Quadrivalent
Then, the report focuses on major leading industry players with information such as company profiles, product picture and specifications, sales, market share and contact information. What’s more, the Flu Vaccine industry development trends and marketing channels are analyzed.
Table of Contents (Key Points):
- Executive Summary
- Market Overview: United States Flu Vaccine Market (2010 – 2024)
- United States Number of Persons Vaccinated with Flu Vaccine (2010 – 2024)
3.1 Number of Children Vaccinated
3.2 Number of Adults Vaccinated
- Key Drivers and Inhibitors of the United States Flu Vaccine Market
4.1 Market Drivers
4.2 Market Inhibitors
- United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification
5.1 Flu Vaccine Price Trends
5.1.1 Pediatric Flu Vaccine Price Trends
5.1.2 Adult Flu Vaccine Price Trends
5.2 United States Flu Vaccine Production, Supply, and Allocation (By Companies)
5.3 United States Flu Vaccine Distribution & Demand
5.4 Flu Vaccine Effectiveness
5.5 Managing Flu with Rapid Diagnostic Testing
5.6 Distribution Method of Flu Vaccination
- United States Flu Vaccine Market Reimbursement & Regulatory System
6.1 Reimbursement System
6.2 Regulation System
- Market Dynamics Mergers, Acquisitions, Key Agreements & Collaborations
7.1 Merger & Acquisitions
7.2 Collaboration Deal
7.3 Licensing, Exclusive & Distribution Agreement Deal
- Flu Vaccine Promising Vaccine in Clinical Development
8.1 Quadrivalent Seasonal Influenza VLP Vaccine
- Flu Vaccine Clinical Trial Insights by Phase, Company & Country
9.1 Year 2017
9.2 Year 2016
- Key Companies Analysis
10.1 Sanofi Pasteur
10.1.1 Business Overview
10.1.2 Flu Vaccine Outlook
10.1.2.1 Fluzone HighDose Vaccine
10.1.2.2 Fluzone Quadrivalent Vaccine
10.1.2.3 Intradermal (ID) Trivalent Flu Vaccine
10.1.2.4 Vaxigrip Vaccine
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.